Valuation: Everest Organics Limited

Market Cap 1.98B 20.51M 18.02M 16.76M 15.38M 28.89M 29.34M 199M 77.74M 971M 77.01M 75.35M 3.36B P/E 2024
675x
P/E 2025 -190x
Enterprise Value 2.39B 24.8M 21.78M 20.25M 18.59M 34.92M 35.46M 241M 93.97M 1.17B 93.09M 91.08M 4.06B EV / Sales 2024
0.75x
EV / Sales 2025 1.79x
Free-Float
23.1%
Yield 2024 *
-
Yield 2025 -
1 day+1.95%
1 week-2.46%
Current month+18.57%
1 month+11.24%
3 months+6.57%
6 months-26.56%
Current year-41.48%
1 week 276.05
Extreme 276.05
319
1 month 245
Extreme 245
344.9
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 106.2
Extreme 106.2
536.4
5 years 95
Extreme 95
536.4
10 years 35.35
Extreme 35.35
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 2015-09-27
Director TitleAgeSince
Director/Board Member 71 2024-11-12
Director/Board Member 47 2007-09-28
Director/Board Member 48 2014-07-29
Change 5-day change 1-year change 3-year change Capi.($)
+1.95%-2.46%-13.13%+141.63% 29.28M
+1.68%+2.13%+16.17%+77.49% 48.36B
+1.52%+2.95%+60.39%+112.28% 35.8B
-0.09%-0.66%-8.03%+31.90% 11.83B
-0.05%-3.10%+13.50%+77.95% 11.48B
-0.93%-0.37%+37.53%+142.08% 9.01B
+0.18%+0.58%+49.62%-9.13% 6.99B
+0.95%-1.59%+12.34%+32.81% 6.7B
+0.18%-1.77%+2.36%+172.36% 6.42B
+3.51%-10.57%-31.55%+0.09% 5.3B
Average +0.89%-1.52%+13.92%+77.95% 14.19B
Weighted average by Cap. +1.08%-0.15%+25.50%+81.65%

Financials

2024 2025
Net sales 1.98B 20.56M 18.06M 16.8M 15.41M 28.96M 29.41M 199M 77.92M 974M 77.19M 75.53M 3.37B 1.6B 16.61M 14.59M 13.57M 12.45M 23.39M 23.75M 161M 62.94M 786M 62.35M 61.01M 2.72B
Net income 1.39M 14.45K 12.7K 11.81K 10.83K 20.36K 20.67K 140K 54.77K 684K 54.26K 53.09K 2.37M -12.9M -134K -118K -109K -100K -189K -192K -1.3M -508K -6.34M -503K -492K -21.93M
Net Debt 570M 5.91M 5.2M 4.83M 4.43M 8.33M 8.46M 57.37M 22.41M 280M 22.2M 21.73M 968M 412M 4.28M 3.76M 3.5M 3.21M 6.03M 6.12M 41.53M 16.23M 203M 16.07M 15.73M 701M
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
355
Date Price Change Volume
26-07-27 296.00 +1.95% 869
26-07-24 ₹290.35 -0.22% 394
26-07-23 ₹291.00 +0.33% 49
26-07-22 ₹290.05 -5.84% 1,642
26-07-21 ₹308.05 -4.44% 2,865
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock